PA007279.m2a: In vivo Grade Recombinant Anti-mouse TIGIT Monoclonal Antibody, Mouse IgG2a Kappa (Clone: 10A7)
Recombinant mouse IgG2a Monoclonal Antibody.
Clone: 10A7.
Isotype: Mouse IgG2a kappa.
Source: The anti-mouse TIGIT monoclonal antibody (clone: 10A7) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: 10A7) specifically binds to the mouse TIGIT protein.
Applications: ELISA, flow cytometry, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the mouse TIGIT protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.
Shipping: The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.
Background
The 10A7 antibody binds to the TIGIT protein (WUCAM, Vstm3 or VSIG9), a novel immune checkpoint receptor with inhibitory function. TIGIT is expressed on T cells and natural killer (NK) cells, and several human cancers, including melanoma, NSCLC, and colorectal cancer. Similar to PD-1, the TIGIT receptor limits antitumor immune response in cancer.
References of anti-mouse TIGIT antibody (10A7)
Integrative analysis of neuroblastoma by single-cell RNA sequencing identifies the NRP2+ neuroblastic progenitor cell state as a novel target for immunotherapy.
Zeng W, et al. Cancer Cell. 2024 Feb 12;42(2):226-240.e8. doi: 10.1016/j.ccell.2023.12.002. PMID: 38168431
To determine whether the NRP2+ neuroblastic progenitor state could be targeted for immunotherapy, we combined anti-TIGIT antibody clone 10A7 with anti-PD-L1 in syngeneic neuroblastoma mouse models. Single-cell suspensions were stained with fluorochrome-conjugated antibodies for flow cytometry. Tumor growth was monitored by caliper measurements twice weekly. The combination therapy significantly reduced tumor burden compared to controls. Flow cytometry data were analyzed using FlowJo software.
Tags: anti-mouse TIGIT; anti-mouse TIGIT 10A7
Enhanced antitumor efficacy of a novel oncolytic vaccinia virus encoding a fully monoclonal antibody against TIGIT.
Zuo S, et al. EBioMedicine. 2021 Jul;69:103441. doi: 10.1016/j.ebiom.2021.103441. PMID: 34120188
The oncolytic vaccinia virus was engineered to express a single-chain variable fragment (scFv) derived from the anti-TIGIT antibody clone 10A7. In vivo studies were conducted in BALB/c mice bearing CT26 tumors. Tumor volumes were measured every 3 days post-treatment. The engineered virus significantly prolonged survival compared to control virus. Flow cytometry confirmed increased CD8+ T cell infiltration in treated tumors.
Tags: anti-mouse TIGIT 10A7 mAb; anti-mouse TIGIT 10A7 antibody in vivo
Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8+ T cell responses.
Waight JD, et al. Immunity. 2022 Jun 14;55(6):1033-1050.e9. doi: 10.1016/j.immuni.2022.04.016. PMID: 35537409
Anti-TIGIT (clone 10A7) and anti-PD-1 antibodies were administered intraperitoneally to mice bearing MC38 tumors. Tumor-bearing mice were treated on days 7, 10, and 13 post-tumor implantation. Flow cytometry was used to assess T cell activation markers. The combination of 10A7 and anti-PD-1 significantly enhanced tumor rejection. Splenic T cells were isolated for ex vivo analysis.
Tags: anti-mouse TIGIT 10A7 antibody in mouse tumor model; function of anti-mouse TIGIT 10A7 antibody
Protective Monoclonal Antibodies against Lethal Staphylococcus aureus Pneumonia in Mice.
Foletti D, et al. Clin Vaccine Immunol. 2011 Oct;18(10):1765-74. doi: 10.1128/CVI.05109-11. PMID: 21849624
Anti-alpha toxin antibodies, including clone 10A7, were tested for protective efficacy in a murine model of necrotizing pneumonia. Mice were challenged intranasally with S. aureus. Survival was monitored for 7 days post-challenge. The 10A7 antibody significantly reduced mortality compared to isotype controls. Lung bacterial burden was quantified by plating homogenates.
Tags: bioactivity of anti-mouse TIGIT 10A7 antibody; anti-mouse TIGIT 10A7 mAb of low endotoxin
Pegvisomant, a growth hormone-specific antagonist, undergoes rapid clearance in the liver with retention in the insulin-like growth factor I response.
Veldhuis JD, et al. J Clin Endocrinol Metab. 2004 Sep;89(9):4521-8. doi: 10.1210/jc.2004-0214. PMID: 15374751
The 10A7 antibody (anti-mouse TIGIT antibody) was used to assess cross-reactivity with pegvisomant in a radioimmunoassay. Pegvisomant was administered intravenously to mice. Serum IGF-I levels were measured by ELISA. Liver clearance was assessed by radiolabeled pegvisomant. Pharmacokinetic profiles were analyzed using compartmental modeling.
Tags: anti-mouse TIGIT 10A7; 10A7 monoclonal antibody
For more references about anti-mouse TIGIT antibody (10A7), please contact our scientific support team with message@sydlabs.com.
Related Recombinant IgG Reference Antibodies:
In vivo grade recombinant mouse IgG2a isotype control antibody
Syd Labs provides the following recombinant anti-mouse TIGIT monoclonal antibodies:
In vivo grade recombinant anti-mouse TIGIT antibodies (clone 1F4)